# Post-Marketing Safety Study in Japan in Participants With High Risk of Severe Exacerbation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine

> **NCT05894525** · — · COMPLETED · sponsor: **ModernaTX, Inc.** · enrollment: 8844 (actual)

## Conditions studied

- SARS-CoV-2

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT05894525
- **Lead sponsor:** ModernaTX, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2022-11-15
- **Primary completion:** 2023-05-26
- **Final completion:** 2023-05-26
- **Target enrollment:** 8844 (ACTUAL)
- **Last updated:** 2024-03-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05894525

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05894525, "Post-Marketing Safety Study in Japan in Participants With High Risk of Severe Exacerbation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05894525. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*